MyronSCzuczmanMD

Internal Medicine • Buffalo, NY

Hematology/Oncology

Professor of Medicine, SUNY Buffalo

Join to view full profile

Are you Dr. Czuczman?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 94 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
Elm And Carlton St
Buffalo, NY 14263
Phone+1 716-845-2300

Fax+1 716-845-3894

Summary

Dr. Myron Czuczman, MD is a board certified internist in Buffalo, New York. He is currently licensed to practice medicine in New York. He is affiliated with KALEIDA Health and is a Professor of Medicine at SUNY Buffalo.

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1988 - 1992
Zucker School of Medicine at Hofstra/NorthwellResidency, Internal Medicine, 1985 - 1988
Pennsylvania State University College of MedicineClass of 1985

Certifications & Licensure

NY State Medical License 1987 - 2026
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2009-2014
Buffalo Spree Magazine Castle Connolly, 2008, 2010-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013

Clinical Trials

506U78 in Treating Patients With Lymphoma Start of enrollment: 2000 May 01
Completed
Phase 2
S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma Start of enrollment: 2001 Mar 01
Active, not recruiting
Phase 3
Rituximab and Galiximab in Treating Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma Start of enrollment: 2005 Jun 01
Completed
Phase 2
A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's Lymphoma Start of enrollment: 2005 Mar 01
Completed
Phase 2
Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Start of enrollment: 2005 Sep 01
Completed
Phase 1, Phase 2
Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment Start of enrollment: 2009 Jan 01
Terminated
Phase 2
Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma Start of enrollment: 2009 Dec 01
Terminated
Phase 1
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 Start of enrollment: 2010 Oct 01
Active, not recruiting
Phase 3
Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia Start of enrollment: 2010 Jan 01
Terminated
Not Applicable
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 02
Terminated
Phase 3
Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma Start of enrollment: 2014 Apr 17
Active, not recruiting
Phase 1
A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia Start of enrollment: 2016 May 11
Completed
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

5 citations
Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trial.
Carla Casulo, Armando Santoro, Guillaume Cartron, Kiyoshi Ando, Javier Munoz
Cancer Reports. 2023-01-01
9 citations
Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy.
Aliyah R. Sohani, Matthew J. Maurer, Sharmila Giri, Brandelyn Pitcher, Amy Chadburn
The American Journal of Surgical Pathology. 2021-03-01
126 citations
ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma.
Grzegorz S. Nowakowski, Annalisa Chiappella, Randy D. Gascoyne, David Scott, Qingyuan Zhang
Journal of Clinical Oncology. 2021-02-23

Press Mentions

Citius Enters Partnership for Phase I/Ib Solid Tumour Treatment TrialSeptember 23rd, 2022
Citius Pharmaceuticals to Host Investor Webcast to Discuss the Acquisition of Late Phase 3 Cancer Immunotherapy I/ONTAK (E7777)October 13th, 2021
Citius Pharmaceuticals : Acquires Dr. Reddy's Laboratories' License for Late-Phase 3 Oncology Immunotherapy (E7777) for the Treatment of Cutaneous T-cell Lymphoma and Other Cancer Indications (Form 8-K)September 7th, 2021
Join now to see all